GOSS Gossamer Bio
- 1.070
- +0.060+5.94%
- 1.020
- -0.050-4.67%
Gossamer Bio News
Several Insiders Invested In Gossamer Bio Flagging Positive News
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gossamer Bio Management to Meet With Oppenhiemer
Bullish Outlook on Gossamer Bio's Seralutinib Efficacy and Market Potential
Oppenheimer Maintains Gossamer Bio(GOSS.US) With Buy Rating, Raises Target Price to $9
Gossamer Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Gossamer Bio Announced Two Oral Presentations And Poster Presentation With Data Relevant To Seralutinib At European Respiratory Society Congress 2024
Analysts Just Made A Notable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Forecasts
With 73% Institutional Ownership, Gossamer Bio, Inc. (NASDAQ:GOSS) Is a Favorite Amongst the Big Guns
Goldman Sachs Maintains Gossamer Bio(GOSS.US) With Buy Rating, Maintains Target Price $8
Buy Rating Affirmed for Gossamer Bio Amidst Financial Growth and Clinical Advancements
Analysts Just Made A Massive Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Forecasts
Barclays Reaffirms Their Hold Rating on Gossamer Bio (GOSS)
Express News | Wedbush Reiterates Outperform on Gossamer Bio, Maintains $4 Price Target
Gossamer Bio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Meiragtx Holdings (MGTX), Spruce Biosciences (SPRB) and Gossamer Bio (GOSS)
Piper Sandler Keeps Their Buy Rating on Gossamer Bio (GOSS)
Gossamer Bio: Cash, Cash Equivalents and Marketable Securities Sufficient to Fund Oper and Capital Expenditures Into 1H 2027 >GOSS
Gossamer Bio Expects to Commence Global Registrational Phase 3 Trial of Seralutinib for Patients With PH-ILD in Mid-2025
Gossamer Bio | 10-Q: Q2 2024 Earnings Report
Analysis
Price Target
No Data
No Data